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Abstract
Protein C inhibitor (PCI) is a heparin-binding serine proteinase inhibitor belonging to the family of serpin proteins. Here we
describe that PCI exerts broad antimicrobial activity against bacterial pathogens. This ability is mediated by the interaction
of PCI with lipid membranes, which subsequently leads to their permeabilization. As shown by negative staining electron
microscopy, treatment of Escherichia coli or Streptococcus pyogenes bacteria with PCI triggers membrane disruption
followed by the efflux of bacterial cytosolic contents and bacterial killing. The antimicrobial activity of PCI is located to the
heparin-binding site of the protein and a peptide spanning this region was found to mimic the antimicrobial activity of PCI,
without causing lysis or membrane destruction of eukaryotic cells. Finally, we show that platelets can assemble PCI on their
surface upon activation. As platelets are recruited to the site of a bacterial infection, these results may explain our finding
that PCI levels are increased in tissue biopsies from patients suffering from necrotizing fasciitis caused by S. pyogenes. Taken
together, our data describe a new function for PCI in innate immunity.
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Introduction
Our early response to an invading pathogen relies to a major
part on our innate immune system. In order to sense and fight an
infection, the human host has developed an arsenal of pattern
recognition proteins that interact with so-called pathogen
associated molecular patterns or PAMPs (for a review see [1]).
Pattern recognition proteins have two major tasks. Some, like toll-
like receptors, evoke an inflammatory response, such as the
induction of proinflammatory cytokines [2], while others are
involved in the direct killing of the pathogen. For instance, there
are scavenger receptors that can act as phagocytic receptors
mediating direct non-opsonic uptake of pathogenic microbes and/
or their products [3]. However, there are also pattern recognition
proteins, such as complement, and antimicrobial peptides that fall
into both categories. For example, the anaphylatoxin peptide C3a
is a potent chemoattractant for phagocytes, but also has a direct
antimicrobial effect [4]; other examples include chemotactic
chemokines and neuropeptides [5,6]. The mode of the antimicro-
bial action of these substances is often based on their ability to
penetrate the cell wall of the pathogen, which eventually leads to
membrane disruption followed by cytosolic leakage and ultimately
to the death of the targeted organism.
The number of antimicrobial peptides/proteins (AMPs) is constantly
increasing and today more than 880 have been described [7]. In order
to display their activity, many AMPs must first be released from their
precursor molecules. Probably one of the best-studied mechanisms is
release of LL-37 from cathelicidin hCAP-18 by the action of proteinase
3 [8]. Notably, in some cases an entire protein can exploit its
antimicrobial activity without any prior processing. Thus, proteins such
as bactericidal/permeability increasing protein, azurocidin and
histidine-rich glycoprotein have been reported to function as
antimicrobial agents (for reviews see [9,10,11]). It is noteworthy that
many of these proteins have an affinity for heparin.
Protein C inhibitor (PCI) is a heparin-binding serine proteinase
inhibitor [12]. As indicated by its name, PCI was originally
reported as an inhibitor of activated protein C, a blood
coagulation factor. Later it was reported that PCI is also found,
apart from plasma, in tears, saliva, cerebral spinal fluid, breast
milk, seminal plasma, and amniotic fluid (for a review see [13]).
Recently, it was described that human PCI is efficiently
internalized by neutrophils and targeted to the nucleus [14].
Interestingly, the authors also found that internalized PCI
promotes phagocytosis of bacteria. As PCI apparently has an
affinity for lipids, we set about to analyze its interaction with
bacterial membranes. To this end we performed a number of
experiments demonstrating for the first time that human PCI is a
potent antibacterial reagent.
Results
Antimicrobial effect of SEK20
Previous work has shown that SEK20, a peptide derived from PCI
(SEKTLRKWLK MFKKRQLELY), and LL-37 (LLGDFFRKSK
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microbial activity against pathogens such as Candida albicans,
Enterococcus faecalis, Escherichia coli, Proteus mirabilis,a n dPseudomonas
aeruginosa [15]. In addition to these pathogens we find in the present
study that SEK20 is also able to kill Bacillus subtilis,Staphylococcus aureus,
and Streptococcus pyogenes. In concordance with the previous report, the
antimicrobial activity of SEK20 was as efficient as that of LL-37
(Table 1). Figure S1 shows the effect of SEK20, LL-37, and GDK25
(a control peptide derived from human high molecular weight
kininogen [16]) on E. coli and S. pyogenes bacteria which were used
throughout this study. Both pathogens are frequently isolated from
patients suffering from severe acute infectious diseases. The broad
antimicrobial activity of SEK20 and its positive net-charge (pI=10.3)
[15], suggest that the peptide does not interact with species-specific
surface proteins of these pathogens, but rather targets their cell
membranes, which is also the point of attack for many other
antimicrobial peptides (for a review see [17]). We therefore tested the
effectofSEK20inapermeabilizationassaybyemployingunilamellar
anionic liposomes [18]. To this end, liposomes were treated with
SEK20 and LL-37 and the subsequent release of carboxyfluorescein
was monitored. Figure 1A shows that SEK20 like LL-37 permea-
bilizes liposomes, suggesting that SEK20 has membrane lytic activity.
A negative side effect of some antimicrobial peptides is that they
not only act on bacterial or fungal surfaces, but also lyse and
ultimately kill eukaryotic cells. We therefore tested the effect of
SEK20 on human erythrocytes and found that SEK20, in contrast
to LL-37, had no hemolytic activity (Figure 1B). Similar results
were obtained when measuring the LDH release from HaCaT
keratinocytes, where LL-37 demonstrated significant release at
higher concentrations, but SEK20 did not (Figure 1C). Taken
together, the results show that SEK20 is a potent antimicrobial
peptide with a broad specificity, but less toxicity for eukaryotic
cells than LL-37.
Antimicrobial activity of PCI
In order to become active, many antimicrobial peptides such as
LL-37 must be released from a precursor molecule [19]. In some
cases, however, this processing is not required and the entire protein
Figure 1. Effect of SEK20 on liposomes, HaCaT keratinocytes,
and whole blood. (A) The effect of SEK20 and LL-37 on liposome
permeabilization was measured in a time-dependent manner. (B) The
hemolytic activity of SEK20 and LL-37 was monitored by incubating
various concentrations of the peptides with human blood followed by
measuring the absorbance at 540 nm. Results are expressed as % of
Triton X-100 induced hemolysis. (C) Serial dilutions of SEK20 and LL-37
were added to HaCaT keratinocytes and cell permeabilization was
measured by determining the release of LDH. All experiments were
performed in triplicates.
doi:10.1371/journal.ppat.1000698.g001
Author Summary
The innate immune system is an integral part of our battle
against an invading pathogen. Antimicrobial peptides and
proteins partake in this fight due to their ability to
perforate the bacterial cell wall, which eventually will cause
the efflux of bacterial cytosolic content and efficient
bacterial killing. Protein C inhibitor (PCI) is a multifunc-
tional heparin-binding serpin which has been implicated in
a number of pathological conditions, including severe
infectious diseases. Here we show that PCI is a potent
antimicrobial agent that is able to destroy the bacterial cell
wall and thereby cause death of the bacteria. Our study
also shows that in contrast to many other antimicrobial
peptides, processing of PCI is not required since the full
length protein exerts its antimicrobial activity, and we
present data demonstrating that PCI is enriched at the
infected site of patients suffering from severe streptococ-
cal infection.
Table 1. Microbial growth inhibition by LL-37 and SEK20.
Bacteria LL-37 SEK20
E. coli 9.1 9.9
P. aeruginosa 7.8 9.0
S. aureus 8.3 8.2
C. albicans 8.2 8.5
B. subtilis 12.9 12.6
Microbial growth inhibition (expressed in mm) was measured using the radial
diffusion assay (see also Material and Methods). Clearance zones with a
diameter more than 4 mm are considered as bacterial killing (n=3; standard
deviation was regularly less then 10%).
doi:10.1371/journal.ppat.1000698.t001
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regionissurfaceexposed asisthecase forhistidine-richglycoprotein
and azurocidin [20,21]. The three-dimensional structure of PCI has
been resolved and a closer examination revealed that a region
spanning the SEK20 sequence forms a hairpin loop sticking out at
the amino terminal part of the protein [22]. It was therefore
tempting to speculate that PCI is by itself antibacterial. To test this,
the effect of PCI on Gram-negative (E. coli) and Gram-positive (S.
pyogenes) bacteria was investigated in viable count assays. Figure 2A
shows that PCI kills E. coli bacteria very efficiently, while its
antimicrobial activity towards S. pyogenes bacteria is slightly reduced
when compared with SEK20 or LL-37 (Figure 2C). Notably, the
antimicrobial effect of PCI was dose-dependent in both cases
(Figure 2B and 2D). Next, we treated PCI with several proteinases
(activated human protein C, factor Xa, plasma kallikrein, thrombin,
elastase, cathepsin G, and proteinase 3) in order to exclude the
possibility that the activity of PCI was achieved upon proteolytic
processing of the protein and subsequent release of a SEK20-
containing peptide. To this end, Western blot experiments with
antibodies against PCI and SEK20 revealed that the protein is
resistant to proteolytic degradation and a fragment spanning the
SEK20 peptide has not been released when incubated with these
enzymes (data not shown). Additional analysis by negative staining
electron microscopy showed that protease treatment did not affect
PCI’s antimicrobial activity (Figure S2). These findings are in line
with reports showing that also other antimicrobial proteins such as
azurocidin are resistant to proteolysis [23]. Finally, we performed
binding assays with radiolabeled PCI in order to investigate the
interaction between the entire PCI molecule and the bacterial
surface. We found that the two bacteria strains tested, E. coli (12%
binding of added radio-labeled protein) and S. pyogenes (27% binding
of added radio-labeled protein), were able to assemble PCI on their
surface. When
125I-PCI bound to streptococci was eluted from the
bacterial surface and run on SDS-PAGE followed by auto-
radiographic analysis, we did not find any signs of degradation
(data not shown), implying that the interaction of PCI with bacteria
does not trigger truncation or processing of the protein. Taken
together our findings show that the entire PCI molecule has
antimicrobial activity and no cleavage of the protein is needed to
generate this effect.
In the next series of experiments we wished to test whether PCI is
able to permeabilize bacteria by the same mechanism as SEK20.
Thus, liposomes were incubated with PCI and the release of
carboxyfluorescein was recorded. The results show that PCI, like
SEK20, has the ability cause a concentration dependent release of
carboxyfluorescein (Figure 2E). To investigate the effect of PCI on
the cell wall of E. coli and S. pyogenes, bacteria were treated with PCI
and analyzed by negative staining microscopy. As seen in Figure 3,
this treatment evoked significant membrane destruction, which was
followed by the extravasation of cytosolic content as detected by the
release of oligonucleotides (Figure 3I). An antimicrobial effect was
also seen when PCI was used at 100 nM which reflects its
concentration in human plasma (Figure S3). Thus, our results show
that PCI mediates its antimicrobial activity by perforating the
bacterial cell membrane followed by the efflux of intracellular
material and subsequent death of the bacteria.
PCI has antimicrobial activity in a plasma environment
In humans, PCI is found in many fluids and secretions including
plasma, seminal plasma, urine, sweat, saliva, tears, milk, and
cerebrospinal fluid (for a review see [24]). Many antimicrobial
peptides/proteins do not display their full activity in a physiolog-
ical environment and require special conditions such as low salt
concentration or low pH. To investigate whether this also applies
for PCI, we studied the interaction of PCI with AP1 bacteria in
human plasma. In contrast to E. coli, S. pyogenes bacteria are not
phagocytozed in human blood and therefore we focused on the
Streptococci only throughout the rest of this study. In a first series
of experiments, we tested whether AP1 bacteria can absorb PCI
from human plasma. To this end, bacteria and normal human
plasma were incubated for 1 h at room temperature. After a
centrifugation step to separate plasma and bacteria and a washing
step, bacteria-bound plasma proteins were recovered by an acid
wash and subjected to Western blot analysis with anti PCI
antibodies. Figure 4 shows that PCI was recruited onto the surface
of AP1 bacteria and a depletion of the protein from human plasma
was also recorded. Based on these findings we wanted to explore
whether PCI can exert its antimicrobial activity in plasma. In
order to do so, we compared the growth of AP1 bacteria in normal
and PCI-deficient plasma. As seen in Figure 5, bacterial
proliferation is significantly accelerated when PCI has been
removed from human plasma, suggesting that PCI is a relevant
antimicrobial agent in human blood.
PCI is associated with activated platelets
PCI is contained within the alpha-granules of platelets and may
be released on activation [25]. It has previously been reported that
M1 protein from Streptococcus pyogenes can stimulate platelet
activation and that activated platelets are present at the site of
streptococcal infection [26]. We therefore set about to determine
whether PCI can be localized on platelets in response to the
physiological activation (ADP) or bacterial activation (M1 protein).
Unstimulated platelets had background levels of PCI on their
surface. Following ADP activation, 11% of the platelet population
had PCI on their surface and this was further increased to 17% on
treatment with M1 protein (Figure 6). A proportion of PCI is likely
to be released directly into the plasma, however our attempts to
quantify platelet derived PCI in plasma failed due to technical
limitations. We can therefore not differentiate between PCI
released from platelets and PCI acquired from plasma and
subsequently bound to platelets. These results do however
demonstrate that PCI can be accumulated on the platelet surface
during streptococcal infection and this may give rise to an
increased PCI concentration at the local site of infection.
PCI is accumulated at the infectious site in a patient with
necrotizing fasciitis caused by S. pyogenes
To test whether PCI levels increase at an infectious site, we
analyzed biopsies derived from four patients with necrotizing
fasciitis caused by S. pyogenes and a healthy control by
immunohistochemistry. Bacterial colonization was demonstrated
by employing an antibody against S. pyogenes, which demonstrates
the presence of streptococci in the biopsy from the patient with
necrotizing fasciitis, but not in the healthy control (Figure 7).
When biopsies were immunostained for PCI, it was found that the
protein was enriched at the infectious site, while it was not
detectable in the control biopsy. PCI recruitment to the site of
infection was localized in cellular infiltrates especially in areas with
a lot of bacteria. To investigate these areas by confocal
microscopy, biopsies were immunostained with antibodies against
S. pyogenes and PCI. Once again the micrographs show that PCI
and Streptococci are distributed throughout the cellular infiltrate
(Figure 8A–C), and are most commonly co-localized (Figure 8D).
Discussion
In the present study we show that PCI has a broad antibacterial
activity towards many Gram negative and Gram positive
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PLoS Pathogens | www.plospathogens.org 3 December 2009 | Volume 5 | Issue 12 | e1000698Figure 2. Antimicrobial effect of PCI on E. coli and S. pyogenes. E. coli 37.4 (A) and S. pyogenes strain AP1 (C) were incubated with SEK20 (6 mM),
LL-37 (6 mM), and PCI (6 mM) or left untreated. A dose dependent effect of PCI (concentration range 0.2 - 6.0 mM) on E. coli 37.4 and AP1 is shown in (B
and D), respectively. To quantify bactericidal activity reaction mixtures were plated on TH broth agar followed by incubation over night at 37uC and
the number of cfus was determined. Statistical significance was determined using one sample T test with a theoretical mean set as 100% survival
based on untreated samples. *** =P,0.001, ** =P,0.01. Values are means, vertical lines show SEM; n=325. (E) The effect of LL-37, and PCI on
liposome permeabilization was measured in a time-dependent manner.
doi:10.1371/journal.ppat.1000698.g002
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required, since the protein is released into plasma in its
antibacterial active form. This is in contrast to many other
antimicrobial peptides/proteins that have to be generated from a
precursor by the action of proteolytic active enzymes. Indeed, our
data show that treatment of PCI with a panel of human
proteinases including neutrophil-borne elastase, proteinases 3 or
cathepsin G, does not diminish the antimicrobial activity of PCI.
This feature has a major advantage, since due to neutrophil
recruitment and their subsequent degranulation, neutrophil-
derived proteinases are enriched at the infected site. Notably,
especially in deep tissue infections such as necrotizing fasciitis with
severe tissue degradation, extremely high proteolytic activity is
recorded which is not only caused by host proteinases, but also by
bacterial virulence factors (for a review see [27]). The increased
protease activity at the site of infection may lead to an inactivation
of antibacterial peptides that are not proteolytic resistant (for a
review see [28]). This has been shown for instance for LL-37,
which is probably cleaved by a streptococcal cysteine proteinase at
the infected site in patients with severe tissue infections and
completely broken down in wound fluids from patients with
chronically infected venous ulcers [29,30]. Our preliminary results
with wound fluids from patients with chronically infected venous
ulcers show that unlike LL-37, PCI is protected from degradation
in this proteolytically potent environment (Malmstro ¨m,
Schmidtchen, and Herwald, unpublished results), suggesting that
Figure 3. Electron microscopic analysis of E. coli and S. pyogenes bacteria treated with PCI. E. coli (A and C) and AP1 (B and D) bacteria
before (A and B) and after (C and D) treatment with PCI 4 mM were subjected to negative staining electron microscopy (bar=1 mm). At higher
magnification, extensive membrane disruption and extravasations of cytoplasmic components is seen in PCI-treated E. coli (F) and AP1 (H) bacteria.
Untreated E. coli (E) and AP1 (G) bacteria served as control (bar=200 nm). (I) AP1 bacteria were incubated with PCI followed by incubation with a
gold-labeled reversed primer coding for M1 protein (arrows), one of the most abundant proteins on the surface of AP1 bacteria (bar=200 nm).
doi:10.1371/journal.ppat.1000698.g003
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bacterial proteinases.
Analysis of biopsies from patients suffering from streptococcal
necrotizing fasciitis reveal an accumulation of PCI at the infectious
site and confocal microscopy studies show that most of the PCI is
found co-localized with streptococci. These data confirm our in
vitro and ex vivo results showing that PCI has an affinity for bacterial
surfaces and they also allow the assumption that the protein exerts
antibacterial activity at an infectious site. As PCI is found at low
concentrations in plasma (4 to 6 mg/ml) an active transport of the
proteins to or its up-regulation at the site of infection is required.
Previous work has shown that platelets can infiltrate the infected
site of patients suffering from soft tissue infections caused by S.
pyogenes [26]. As the alpha-granules of platelets constitute a storage
of PCI [25], we propose a model where PCI is released from
platelets that are recruited to the site of infection. Unfortunately,
we were not able to distinguish whether PCI was released from the
a-granules or from the surface of platelets that have absorbed PCI
from plasma. However, considering that platelets contain very
little PCI (160 ng PCI/2610
9 cells) [25], it seems more likely that
they absorbed it from plasma. At this point we cannot exclude that
PCI synthesis is induced at the infectious site and therefore, in
ongoing studies we address whether PCI generation can be
triggered in different cell lines, including HepG2 cells, upon
stimulation with inflammatory substances, such as IL-1b, IL-6, or
TNFa.
The affinity of PCI for negatively charged lipids may help
explain the mechanism by which the bacterial cell wall is
disrupted. As visualized by negative staining electron microscopy,
the interaction of PCI with bacteria leads to destruction of the
bacterial cell wall and the release of cytosolic content, eventually
leading to bacterial killing. Recently, Baumga ¨rtner et al. reported
that PCI is avidly internalized by human polymorph nuclear
neutrophils (PMNs), and this involves phosphatidyl-ethanolamines
[14]. The authors also reported that this interaction enhances the
uptake of E. coli bacteria and, thus they suggest an important role
for PCI in innate immunity [14]. Considering that the PCI-evoked
release of bacterial cytosolic content will cause additionally
Figure 4. PCI is absorbed from human plasma by AP1 bacteria.
S. pyogenes bacteria were incubated with citrated human plasma for
1 h. The bacterial cells were collected, washed with PBS, and bound
proteins were eluted with 0.1 M glycine–HCl, pH 2.0. The eluted
proteins were precipitated and dissolved in SDS sample buffer and
subjected to Tricine-SDS gel electrophoresis followed by Western blot
analysis and immunodetection with antibodies against PCI. (1) Human
plasma (diluted 1:100), (2) bacteria-bound plasma proteins and (3)
human plasma (1:100) after removal of bacteria and bacteria-bound
plasma proteins.
doi:10.1371/journal.ppat.1000698.g004
Figure 5. PCI inhibits bacterial growth in plasma. S. pyogenes
strain AP1 was grown in normal human plasma or PCI-deficient plasma
at 37uC for 8 h. Bacterial growth was then followed by plating
appropriate dilutions of the bacterial solutions on TH agar plates at the
indicated time points. Plates were incubated at 37uC over night and
cfus were determined. A representative experiment of 5 is shown.
doi:10.1371/journal.ppat.1000698.g005
Figure 6. PCI associated with platelets. Platelet rich plasma was
incubated with buffer, ADP (5 mM), or M1 protein (1 mg/ml). After 5
minutes, PCI was detected on the platelet surface using flow cytometry.
The percentage of the platelet population that presented PCI on their
surface was determined using Cell Quest Software (BD Biosciences).
ADP and M1 protein stimulated PCI associated to platelets. Statistical
significance was determined using students T test. *** =P,0.001.
Values are means, vertical lines show SEM; n=4.
doi:10.1371/journal.ppat.1000698.g006
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the host has developed a counteracting mechanism. Uptake of
PCI-opsonized bacteria by PMNs before their destruction may
lead to decreased inflammatory reactions, while still guaranteeing
an efficient killing of the pathogen. Thus a synergistic effect of PCI
resulting in bacterial recognition by PCI and their subsequent
uptake by phagocytic cells followed by intracellular killing, is an
attractive concept that would lead to a clearance of the infection
and a dampening of inflammatory responses.
Taken together, our studies show a novel function for PCI as an
antimicrobial agent against a broad arsenal of bacterial pathogens.
This is mediated by the ability of PCI to interact with lipids
leading to the efflux of bacterial cytosolic content. When analyzing
tissue biopsies we find an accumulation of PCI at the infectious
site. These findings suggest an important and novel role of PCI in
innate immunity.
Materials and Methods
Ethics statement
The Human Subjects Review Committee of the University of
Toronto and of Lund University approved the studies, and
written, informed consent from the patients and volunteers was
received.
Reagents
Fresh frozen plasma from healthy individuals were obtained
from the blood bank at Lund University Hospital, Lund, Sweden,
and kept frozen at 280uC until use. Protein C Inhibitor deficient
plasma was prepared as described [31]. M1 protein was purified
from the supernatant of S. pyogenes MC25, as previously described
[32].
Antimicrobial peptides and protein
SEK20 (SEKTLRKWLKMFKKRQLELYL) and LL-37
(LLGDFFRKSK EKIGKEFKRI VQRIKDFLRN LVPRTES)
were synthesized by Innovagen AB, Lund, Sweden. The purity
(.95%) and molecular weight of these peptides was confirmed by
mass spectral analysis (MALDI.TOF Voyager). Recombinant
protein C inhibitor was purified as previously described [33].
Microorganisms
Escherichia coli 37.4 and ATCC25922, Pseudomonas aeruginosa
ATCC27853, Staphylococcus aureus ATCC29213, Bacillus subtilis
Figure 7. Immuno-histochemical analysis of tissue biopsies. Tissue biopsies were obtained at the epicenter of the infection from four patients
with necrotizing fasciitis caused by Streptococcus pyogenes. For comparison, a skin biopsy was obtained from a healthy volunteer. The biopsies were
sectioned and stained for Streptococcus pyogenes (GAS), PCI, and control staining where the primary antibody was omitted (ctrl). The figure shows 1
representative biopsy from a patient and the healthy control.
doi:10.1371/journal.ppat.1000698.g007
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albicans ATCC90028 were grown as described elsewhere [34]. The
Streptococcus pyogenes AP1 (40/58) strain of the M1 serotype was
provided by the WHO (World Health Organization) Streptococcal
Reference Laboratory in Prague, Czech Republic and cultured as
previously described [35].
Bactericidal assays
Radial diffusion assays were performed as described previously
[36]. Briefly, bacteria were grown to mid-logarithmic phase in
10 ml full strength 3% (w/v) tryptic soy broth (TSB) (Becton
Dickinson, Franklin Lakes, NJ, USA). The bacteria were washed
once in 10 mM Tris, pH 7.4 and then 2610
6 CFU were added to
5 ml of the underlay agarose gel consisting of 0.03% (w/v) TSB,
1% (w/v) low-electroendosmosistype (Low-EEO) agarose (Sigma)
and a final concentration of 0.02% (v/v) Tween-20. The underlay
was poured into a Petri dish. After the agarose had solidified,
4 mm diameter wells were punched and 6 ml of test samples were
added to each well. Samples were allowed to diffuse into the gel for
3 h in 37uC and then the underlay gel was covered with 5 ml
overlay (6% TSB, 1% Low-EEO agarose). Antibacterial activity
was visualized as a clear zone around each well after overnight
incubation at 37uC of the plate. The activities of the peptides are
presented as diameter of clear zone-well diameter.
Hemolytic assay
EDTA-blood was centrifuged at 800 g for 10 min and plasma
and buffy coat removed. Erythrocytes were washed three times
and resuspended in 5% PBS, pH 7.4. The cells were incubated
with end-over-end rotation for 1 h at 37uC in the presence of
SEK20 or LL-37 (3–60 mM). 2% Triton X-100 (Sigma-Aldrich)
served as positive control. The samples were then centrifuged at
800 g for 10 min. Hemoglobin release was measured as the
absorbance at l 540 nm and the values are expressed as % of
TritonX-100 induced hemolysis.
Liposome preparation and leakage assay
Dry lipid films were prepared by dissolving dioleoylpho-
sphatidylcholine (Avanti Polar Lipids, Alabaster, AL) (30 mol%),
dioloeolphosphatidic acid (30 mol %) and cholesterol (Sigma, St
Louis, MO) (40 mol%) in chloroform, and removing the solvent
by evaporation under vacuum overnight. Subsequently, buffer
solution containing 10 mM Tris, pH 7.4, was added together with
0.1 M carboxyfluorescein (CF) (Sigma, St Louis, MO). After
hydration, the lipid mixture was subjected to eight freeze-thaw
cycles consisting of freezing in liquid nitrogen and heating to 60uC.
Unilamellar liposomes with a diameter of about 140 nm (as found
with cryo-TEM and dynamic light scattering; results not shown)
were generated by multiple extrusions through polycarbonate
filters (pore size 100 nm) mounted in a LipoFast miniextruder
(Avestin, Ottawa, Canada). Untrapped carboxyfluorescein was
then removed by filtration through two subsequent Sephadex G-
50 columns with the relevant Tris buffer as eluent. Both extrusion
and filtration was performed at 22uC. In the liposome leakage
assay, the well known self-quenching of CF was used. Thus, at
100 mM CF is self-quenched, and the recorded fluorescence
Figure 8. Co-localization of PCI and Streptococci at the infectious site. Tissue biopsies (see Figure 7) were stained for (Alexa 594, red, A) and
S. pyogenes (Alexa 488, green, B). Cellular infiltrates are indicated in blue by the DNA binding stain DAPI (C). The yellow stain illustrates areas where
bacteria and PCI are co-localized (D). Bar: 5 mm.
doi:10.1371/journal.ppat.1000698.g008
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from the liposomes, released CF is dequenched, and hence
fluoresces. The CF release was determined by monitoring the
emitted fluorescence at 520 nm from a liposome dispersion
(10 mM lipid in 10 mM Tris pH 7.4). An absolute leakage scale
is obtained by disrupting the liposomes at the end of the
experiment through addition of 0.8 mM Triton X100 (Sigma, St
Louis, MO), thereby causing 100% release and dequenching of
CF. A SPEX-fluorolog 1650 0.22-m double spectrometer (SPEX
Industries, Edison, NJ) was used for the liposome leakage assay.
Lactate dehydrogenase (LDH) assay
HaCaT keratinocytes were grown to confluence in 96 well
plates (3000 cells/well) in DMEM, 10% FCS. The medium was
removed and the cells were subsequently washed with 100 ml
DMEM. 100 ml of SEK20 or LL-37 (0, 3, 6, 30, 60 mM) diluted in
DMEM were added in triplicates. The LDH based TOX-7 kit
(Sigma-Aldrich) was used to measure the viability of the cells.
Viable count assay
Bacteria were cultivated overnight in Todd-Hewitt medium
(TH; Difco) at 37uC. 250 ml were transferred to 10 ml TH-
medium and grown to mid-log phase (A620<0.4). The bacterial
solution was washed 3 times in 10 mM Tris, 5 mM glucose,
pH 7.4 (Tris-HCl buffer). 5 ml( 2 610
6 cfu/ml) was added to the
respective antimicrobial substance at a total volume of 17 ml and
incubated for 1 h at 37uC. After the incubation 500 ml Tris buffer
was added to the mixture and 100 ml was transferred to Todd-
Hewitt broth agar plate to determine the bacterial growth. Plates
were incubated overnight at 37uC and the number of colony
forming units (cfu) was determined.
Electron microscopy
The antimicrobial effect of PCI against E. coli and S. pyogenes was
analyzed by negative staining and electron microscopy as
previously described [37]. Bacteria were diluted to a 1% solution
with TBST (20 mM Tris, 150 mM NaCl, 0.05% Tween, pH 7.4)
and 10 ml incubated with PCI at a concentration of 4 mM for
90 min at 37uC. 5 ml aliquots were adsorbed onto carbon-coated
grids for 1 min, washed with two drops of water, and stained on
two drops of 0.75% uranyl formate. The grids were rendered
hydrophilic by glow discharge at low pressure in air. Specimens
were observed in a Jeol JEM 1230 electron microscope operated at
60 kV accelerating voltage. Images were recorded with a Gatan
Multiscan 791 CCD camera.
Plasma absorption
Bacteria, grown to mid-exponential growth phase were washed
and resuspended in PBST (PBS+0.05% Tween-20). 250 ml of the
bacterial solution (2610
9 bacteria/ml) was incubated with 1.5 ml
citrate plasma for 1 h at 37uC. The bacterial cells were collected,
washed with PBST including 0.5 M NaCl and bound proteins
eluted with 0.1 M glycine–HCl, pH 2.0. The pH of the eluted
material was raised to 7.5 by addition of 1 M Tris. Precipitated
material was dissolved in SDS sample buffer and subjected to
Tricine-SDS gel electrophoresis and Western blot analysis.
Western blot analysis
Samples were boiled for 5 min in an equal volume of sample
buffer containing 2% SDS and 5% 2-mercaptoethanol and run on
SDS-PAGE. Bio-rad kaleidoscope prestained standards were used
as molecular weight markers. Separated proteins were transferred
to polyvinylidene difluoride (PVDF) membranes (Amersham
Biosciences). Membranes were blocked with PBST (PBS+0.05%
Tween-20) containing 5% dry milk powder (blocking buffer)
overnight at 4uC and then incubated with primary antibodies
(rabbit anti-PCI K88032 1:1000) in blocking buffer for 1 h at
37uC. After a washing step with PBST with 0.35 M NaCl, the
membranes were incubated with HRP-conjugated secondary
antibodies (goat anti-rabbit IgG 1:10000) in blocking buffer for
1 h at 37uC. The membranes were washed and bound antibodies
detected by chemiluminescence.
Bacterial growth in PCI deficient plasma
S. pyogenes was cultivated in human plasma and PCI-deficient
plasma at 37uC. Bacterial suspensions were diluted 10000 times in
10 mM Tris, containing 5 mM glucose (pH 7.4) and transferred to
TH-agar plates at different time points (0, 4 and 8 h) to monitor
bacterial growth. Plates were incubated overnight at 37uC and the
number of bacteria determined.
Platelet analyses using flow cytometry
Blood samples were collected from healthy donors who had not
taken antiplatelet medication in the previous ten days. Five ml of
blood was collected into citrated vacuum tubes. Platelet-rich
plasma (PRP) was prepared by centrifugation at 1506g for 10
minutes. Twenty ml of PRP was incubated at room temperature
with 25 ml of HEPES buffer pH 7.4, either in the presence or
absence of 5 mM adenosine diphosphate (ADP) or M1 protein
(1 mg/ml). After 5 minutes, primary antibodies were added (rabbit
anti-PCI K88032 1:100) and incubated for 5 minutes. Five mlo f
fluorochrome conjugated secondary antibody (anti Rabbit FITC)
was then added and after 5 minutes the incubation was stopped by
addition of 0.5% formaldehyde in ice cold PBS. Samples were
analysed using a FACSCalibur flow cytometer in logarithmic
mode with a gate setting on the platelet population. 50,000 cells
were acquired and analysed using Cell Quest software (Becton
Dickinson).
Immunohistochemical staining of tissue biopsies
A snap-frozen tissue biopsy collected from patients with
necrotizing fasciitis caused by group A streptococcus (GAS) was
stained and compared with a snap-frozen punch biopsy taken from
a healthy volunteer. The biopsies were cryostat-sectioned to 8 mm,
fixed in 2% freshly prepared formaldehyde in PBS and stained.
Tissue sections were initially blocked with 10% fetal calf serum in
Earl’s balanced salt solution (BSS) with 0.1% saponin for 30
minutes at room temperature, followed by additional blocking
with 1% H2O2 in BSS-saponin and an avidin and biotin blocking
(Vector laboratories). Primary antibodies were diluted in BSS
solution containing saponin and 0.02% NaN3 and incubated over
night at room temperature. S. pyogenes bacteria were identified with
a polyclonal rabbit antiserum specific for the Lancefield group A
carbohydrate (diluted 1:10,000; Difco), while PCI was identified
with a polyclonal rabbit antiserum (1 mg/ml) K88032. After
incubation, tissue sections were washed and blocked with 1%
normal goat serum in BSS-saponin before addition of biotinylated
goat anti-rabbit IgG (diluted 1:500, Vector laboratories) diluted in
1% normal goat serum in BSS-saponin. Avidin-peroxidase
solution was added (Vectastain-Elite; Vector Laboratories) and
the color reaction developed by the addition of 3,3-diaminobenzi-
dine (Vector Laboratories) followed by counterstaining with
hematoxylin. PCI and streptococci were also visualized with
immunoflourescence stainings. The tissue was initially blocked
with an avidin/biotin blocking kit (Vector laboratories) whereafter
PCI was identified with a monoclonal mouse antibody (5 mg/ml)
API-93 followed by a blocking step with 1% normal goat serum.
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against mouse IgG (diluted 1:600, Dako), and subsequently with a
streptavidin-conjugated fluorophor (Alexa 594, diluted 1:500,
Molecular Probes). After yet another round of blocking with
avidin/biotin streptococci were detected using a biotinylated
polyclonal rabbit antiserum specific for the Lancefield group A
carbohydrate (16 mg/ml, Difco) followed by incubation with a
second streptavidin-conjugated fluorophore (Alexa 488, diluted
1:600, Dako). All antibodies and fluorochromes were diluted in
PBS-saponin-BSA-c, while washes were done with PBS-saponin.
The immunofluorescence stainings were evaluated by a Leica
confocal scanner TCP SP II coupled to a Leica DMR microscope.
Statistical analysis
Statistical analysis was performed using GraphPadPrism 4.00.
For viable count data the p value was determined using a one
sample T test with a theoretical mean set as 100% survival based
on untreated samples. For flow cytometry data the p value was
determined using students T test.
Supporting Information
Figure S1 Antimicrobial effect of LL-37, SEK20, and GKD25
on E. coli and S. pyogenes. E. coli 37.4 (A) and S. pyogenes strain AP1
(B) were incubated with LL-37 (4 mM), SEK20 (4 mM), GKD25
(4 mM), or left untreated. GDK25 is a peptide derived from high
molecular weight kininogen which has been shown to lack
antimicrobial activity [16]. To quantify bactericidal activity
reaction mixtures were plated on TH broth agar followed by
incubation over night at 37uC and the number of cfus was
determined. E. coli (C and D) and AP1 (E and F) bacteria before (C
and E) and after (D and F) treatment with GKD25 (2 mM) were
subjected to negative staining electron microscopy (bar=1 mm).
The figure shows that LL-37 and SEK20 possess antimicrobial
activity, but not GDG25.
Found at: doi:10.1371/journal.ppat.1000698.s001 (6.08 MB TIF)
Figure S2 Antimicrobial effect of protease-treated PCI on E. coli
and S. pyogenes. PCI (100 nM, final concentration) was incubated
with human activated protein C (aPC), factor Xa (FXa), plasma
kallikrein (PKa), thrombin, elastase, cathepsin G (cath. G),
proteinase 3 (prot. 3) or left untreated (PCI) for 30 min at 37uC.
All proteinases were used at a final concentration of 10 nM. PCI
and proteinases-treated PCI was incubated with E. coli and S.
pyogenes bacteria as described and Materials and Methods followed
by negative staining electron microscopy analysis. Untreated
bacteria were used as negative control (A). The figure shows that
proteinase-treatment did not impair the antimicrobial activity of
PCI. The percentage killing judged from the electron microscopic
analysis is indicated in each micropgraph.
Found at: doi:10.1371/journal.ppat.1000698.s002 (8.73 MB TIF)
Figure S3 Antimicrobial effect of PCI (100 nM) on E. coli and S.
pyogenes. E. coli (A and C) and S. pyogenes strain AP1 (B and D) were
incubated PCI (C and D) at a concentration of 100 nM, or left
untreated (A and B) and analyzed by negative electron microcopy.
Scale bar=200 nm).
Found at: doi:10.1371/journal.ppat.1000698.s003 (6.28 MB TIF)
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